Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc's. (“HTG”) mission is to empower precision medicine at the local level. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of multiplexed profiling panels that leverage HTG’s proprietary target protection chemistry. In 2014, the company launched the HTG EdgeSeq system that combines the power of HTG Edge chemistry and automation with NGS technology. The HTG EdgeSeq system enables fast and easy use of NGS instruments for molecular profiling.

Stock Quote

Copyright Nasdaq. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Announces Preliminary Fourth Quarter and Full Year 2017 Unaudited Financial Results and Provides Initial 2018 Revenue Guidance
Fourth quarter 2017 revenue expected to be between $6.9 and $7.2 million Full year 2017 revenue expected to be between $13.8 and $14.1 million Initial full year 2018 revenue guidance of $20.0 to $25.0 million TUCSON, Ariz. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
Toggle Summary HTG Molecular Diagnostics Expands its Collaboration with Merck KGaA, Darmstadt, Germany
Signs Master Collaboration Agreement for Assay Development and Manufacturing of Kits Supporting Biomarker Research Programs TUCSON, Ariz. and DARMSTADT, Germany , Dec. 26, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for
Toggle Summary HTG Molecular Diagnostics to Participate in Corporate Access Event in San Francisco, January 8 – 10, 2018
TUCSON, Ariz. , Dec. 20, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (NASDAQ:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that its senior management team will host institutional investor and partnering meetings at the
Toggle Summary HTG Molecular Diagnostics Reports 2017 Third Quarter Earnings
Revenue increased 307% and 87%, respectively, compared to the three and nine month periods in the prior year driven by development efforts supporting Pharma clinical programs TUCSON, Ariz. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
Toggle Summary HTG Molecular Diagnostics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Tuesday, November 7
TUCSON, Ariz. , Oct. 20, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that it will report its financial results for the three and nine months ended September 30, 2017

Stock Chart

SEC Filings

Filing date Description

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event

Statement of changes in beneficial ownership of securities